Electroceuticals market seen reaching $36.53 billion by 2030

The electroceuticals market is projected to grow from $25.94 billion in 2026 to $36.53 billion by 2030, driven by demand for drug-free therapies, personalized medicine and more neurostimulation adoption. North America held the largest share in 2025 as chronic disease rates and regulatory approvals continue to support demand.

Why it matters: - Electroceuticals are moving from a niche category toward a larger share of medical-device spending as drug-free and minimally invasive treatments gain traction. - Growth in chronic neurological and long-term conditions is expanding the pool of patients that could benefit from neuromodulation and bioelectronic therapies. - The market’s projected 8.9% CAGR through 2030 signals continued investment in implantable devices, remote monitoring and artificial intelligence tools for therapy optimization.

What happened: - The Business Research Company projected the global electroceuticals market will rise from $25.94 billion in 2026 to $36.53 billion by 2030. - The forecast implies an 8.9% compound annual growth rate over the period. - The report said North America held the largest regional share of the electroceuticals market in 2025. - The analysis also covered Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - The market had expanded from $23.96 billion in 2025 to $25.94 billion in 2026, a CAGR of 8.2%. - Past growth was driven by advances in neurostimulation technology, rising chronic neurological disorders, stronger clinical validation, wider use of implantable devices and broader acceptance of bioelectronic medicine. - Future growth is tied to investment in personalized medicine and demand for therapies that do not rely on drugs. - Additional drivers include closed-loop stimulation systems, remote monitoring adoption and more regulatory approvals for electroceutical devices. - Key trends include greater use of implantable neuromodulation devices, more non-invasive therapies, AI integration for therapy optimization, growth in personalized bioelectronic treatments and more precise neural stimulation. - Electroceuticals combine electronics, biology and medicine to use electrical stimulation for treatment. - The therapies target neural circuits and bioelectrical systems to address medical conditions. - The approach is designed to reach specific nerves, tissues or organs and can offer more precise and minimally invasive treatment options than traditional methods. - A January 2023 National Library of Medicine estimate said the U.S. population age 50 and older with at least one chronic condition is expected to nearly double by 2050 to 142.66 million.

Between the lines: - The report points to a shift toward device-based care in areas where drugs can be less effective, less targeted or harder to tolerate. - Chronic disease growth strengthens the case for electroceuticals because the therapies can provide longer-term symptom management and may help in treatment-resistant cases. - North America’s lead suggests the region remains the early commercial center for neuromodulation and bioelectronic medicine.

What's next: - The market is likely to keep expanding as more devices win approvals and as clinicians adopt closed-loop and remote-monitoring systems. - Growth will likely track broader use of personalized medicine and non-invasive treatment platforms. - The Business Research Company said its 2026 report package includes TAM analysis, company scoring matrices, forecasting dashboards, hotspots infographics and updated trend graphics. - The company offered a free sample report and the full market report through its website.